Consistent with the NLRP3 inflammasome’s role in over-secretion of IL-1β and IL-18 in CAPS patients18, IL-1 biologics are used for the treatment of these disorders19. This evidence concerns the gene IL18 and cryopyrin-associated periodic syndrome.